Evidence map›Paper›PMID 38827177›Full record

ReviewTherapeutic advances in medical oncology2024

PARP inhibitors in prostate cancers, is it time for combinations?

Diego Teyssonneau, Charles Dariane, Eric Barret, Jean-Baptiste Beauval, Laurent Brureau, Gaëlle Fiard, Gaëlle Fromont, Gilles Créhange, Mathieu Gauthé, Alain Ruffion and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in medical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Diego TeyssonneauDepartment of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, Bordeaux 33000, France.ORCID https://orcid.org/0000-0002-9687-3759
Charles DarianeDepartment of Urology, Hôpital Européen Georges-Pompidou, APHP, Paris University, U1151 Inserm-INEM, Necker, Paris, France.
Eric BarretDepartment of Urology, Institut Mutualiste Montsouris, Paris, France.
Jean-Baptiste BeauvalDepartment of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France.
Laurent BrureauDepartment of Urology, CHU de Pointe-à-Pitre, University of Antilles, University of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Pointe-à-Pitre, France.
Gaëlle FiardDepartment of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, Grenoble, France.
Gaëlle FromontDepartment of Pathology, CHRU Tours, Tours, France.
Gilles CréhangeDepartment of Radiation Oncology Curie Institute, Paris, France.
Mathieu GauthéDepartment of Nuclear Medicine, Scintep, Grenoble, France.
Alain RuffionService d'Urologie Centre Hospitalier Lyon Sud, Hospices Civils de Lyon.
Raphaële Renard-PennaAP-HP, Radiology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France.
Romain MathieuDepartment of Urology, University of Rennes, Rennes, France.
Paul SargosDepartment of Radiotherapy, Institut Bergonié, Bordeaux, Aquitaine, France.
Morgan RouprêtAP-HP, Urology, GRC 5 Predictive Onco-Uro, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France.
Guillaume PloussardDepartment of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France.
Guilhem RoubaudDepartment of Medical Oncology, Institut Bergonié, Bordeaux, Aquitaine, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite several improvements in outcomes, metastatic prostate cancer remains deadly. Alterations in the homologous recombination repair (HRR) pathway are associated with more aggressive disease. Olaparib and rucaparib, two poly-ADP-ribose polymerase (PARP) inhibitors, have received approval from the authorities of several countries for their anti-tumoral effects in patients with metastatic castration-resistant prostate cancers harboring HRR gene alterations, in particular

Indexed as

DNA repairhomologous recombination repairmetastatic prostate cancersPARP inhibitors

Identifiers

PMID38827177
PMCPMC11143875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.